Ligachem Bio announced on July 9 that it has received a milestone payment following the first patient dosing of 'LCB97', which was out-licensed to Ono Pharmaceutical.


Due to confidentiality clauses in the contract, the amount received has not been disclosed. However, the milestone payment exceeds 10% (ten percent) of Ligachem Bio's consolidated sales of approximately KRW 141.5 billion last year, making it subject to mandatory disclosure.



If future clinical trials, approvals, or commercialization do not materialize, the technology transfer agreement may be terminated. However, even if the contract is terminated, there is no obligation to return the milestone payment.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing